PBI 1101

Drug Profile

PBI 1101

Alternative Names: PBI-1101

Latest Information Update: 13 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProMetic Life Sciences
  • Class Anti-inflammatories
  • Mechanism of Action Peptide hydrolase inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 13 Jul 2009 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
  • 19 Nov 2004 PBI 1101 is available for licensing (http://www.prometic.com)
  • 19 Aug 2003 Preclinical trials in Inflammation in Canada(unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top